论文部分内容阅读
目的:对我院93例结直肠癌患者4种化疗方案化疗后骨髓抑制发生情况进行回顾分析,为临床安全用药提供参考。方法:收集整理我院2014年4月~2015年3月共93例结直肠癌患者化疗后的骨髓抑制发生情况,根据患者情况及化疗方案分析其发生特点及影响因素。结果:93例结直肠患者经化疗后,发生骨髓抑制39例(41.94%),其中重度骨髓抑制为7例(17.95%);骨髓抑制发生时间主要集中在化疗后1~2周内;不同性别、年龄患者骨髓抑制构成比差异无统计学意义;多药联合化疗所致的骨髓抑制发生率(50%)较单药(27.27%)高,差异有统计学意义(P<0.05)。结论:化疗方案与患者发生骨髓抑制概率密切相关。因此,临床医生与药师应慎重选择化疗方案,密切监测骨髓抑制发生时间,采取积极措施降低骨髓抑制的发生风险,促进患者用药安全。
OBJECTIVE: To retrospectively analyze the occurrence of myelosuppression after chemotherapy of three kinds of chemotherapy regimens in 93 patients with colorectal cancer in our hospital, so as to provide a reference for clinical safe medication. Methods: A total of 93 cases of colorectal cancer patients with myelosuppression after chemotherapy were collected from April 2014 to March 2015 in our hospital. The characteristics and influential factors of the myelosuppression were analyzed according to the patient’s condition and chemotherapy regimen. Results: The bone marrow suppression occurred in 39 cases (41.94%) of 93 cases of colorectal cancer after chemotherapy, of which 7 cases (17.95%) had severe myelosuppression. The time of bone marrow suppression mainly concentrated within 1 ~ 2 weeks after chemotherapy. There was no significant difference in the constituent ratio of bone marrow suppression in patients with age. The incidence of myelosuppression caused by multi-drug combination chemotherapy (50%) was higher than that of single drug (27.27%), the difference was statistically significant (P <0.05). Conclusion: The chemotherapy regimen is closely related to the probability of myelosuppression in patients. Therefore, clinicians and pharmacists should carefully select the chemotherapy regimen, closely monitor the time of myelosuppression, take active measures to reduce the risk of bone marrow suppression, and promote the safety of patients medication.